Sign In
Buy PIRS
$13.60
+0 (+0%)
At Close: Mar 12, 2025
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
09:56am, Wednesday, 10'th May 2023
Pieris Pharmaceuticals (PIRS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.07 per share a year ago.
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
04:30pm, Tuesday, 02'nd May 2023
BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolo
Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call Transcript
03:40pm, Wednesday, 29'th Mar 2023
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q4 2022 Results Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Ste
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates
09:59am, Wednesday, 29'th Mar 2023
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 15.38% and 10.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
08:00am, Wednesday, 23'rd Nov 2022
BOSTON, MA / ACCESSWIRE / November 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® te
Pieris Pharmaceuticals, Inc. (PIRS) Q3 2022 Earnings Call Transcript
12:23pm, Wednesday, 02'nd Nov 2022
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Thomas Bures - SVP & CFO Stephen Yoder - CEO, President & Director Shane O
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
08:00am, Wednesday, 26'th Oct 2022
BOSTON, MA / ACCESSWIRE / October 26, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
04:01pm, Thursday, 08'th Sep 2022
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® te
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript
05:14pm, Saturday, 06'th Aug 2022
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder - President and Chief Executi
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates
01:35pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates
11:18am, Thursday, 04'th Aug 2022
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
07:20am, Thursday, 28'th Jul 2022
BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
08:00am, Thursday, 02'nd Jun 2022
BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolo
Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
01:35pm, Wednesday, 18'th May 2022 Zacks Investment Research
Pieris Pharmaceuticals (PIRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst
Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:17am, Wednesday, 18'th May 2022
Pieris Pharmaceuticals (PIRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst
